PSC
ALXO icon

Piper Sandler & Co’s ALX Oncology ALXO Stock Holding History

Piper Sandler & Co’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,900
Closed -$223K – 22
2020
Q3 		$223K Buy
+5,900
New +$232K 0.17% 17

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Piper Sandler & Co's ALXO Position: Q4 2020 in Review

Piper Sandler & Co sold out of ALX Oncology (ALXO) in Q4 2020, closing a stake of 5,900 shares — an estimated $223K sold.

Piper Sandler & Co first reported a position in ALXO in Q3 2020 and held it in 1 quarter. The position peaked at $223K in Q3 2020. 89 funds tracked by Wall St. Rank hold ALXO as of Q4 2020.

  • Piper Sandler & Co reported no remaining ALX Oncology position as of Q4 2020 after selling out during the quarter.
  • Piper Sandler & Co sold 5,900 ALX Oncology shares in Q4 2020, an estimated $223K.
  • Piper Sandler & Co first reported a position in ALX Oncology in Q3 2020 and held it in 1 quarter.
  • Piper Sandler & Co's ALX Oncology position peaked at $223K in Q3 2020.
  • 89 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2020.

Based on Piper Sandler & Co's 13F filing for Q4 2020, filed 11 Feb 2021.